Table 1.
Characteristics of treatment naïve PLWH initiating care in the CNICS Cohort between 2007 and 2015
| Characteristic | Total=5373 | Modifieda=2285 | Continueda=3088 |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Age (years) | |||
| <30 | 1468 (27) | 596 (26) | 872 (28) |
| 30–45 | 2511 (47) | 1049 (46) | 1462 (47) |
| >45 | 1394 (26) | 640 (28) | 754 (25) |
| Race | |||
| White | 2638 (49) | 1098 (48) | 1540 (50) |
| Black | 2015 (38) | 911 (40) | 1104 (36) |
| Other | 720 (13) | 276 (12) | 444 (14) |
| Sex | |||
| Male | 4546 (85) | 1841 (81) | 2705 (88) |
| Female | 827 (15) | 444 (19) | 383 (12) |
| Insurance | |||
| Private | 663 (12) | 248 (11) | 415 (13) |
| Public | 997 (19) | 451 (20) | 546 (18) |
| Uninsured | 1336 (25) | 495 (21) | 841 (27) |
| Unknown | 2377 (44) | 1091 (48) | 1286 (42) |
| Transmission Mode | |||
| MSM/Homosexual | 3463 (64) | 1380 (60) | 2083 (67) |
| Heterosexual | 1160 (22) | 540 (24) | 620 (20) |
| IVDU | 332 ( 6) | 192 ( 8) | 140 ( 5) |
| Other | 418 ( 8) | 173 ( 8) | 245 ( 8) |
| VL at regimen initiation (copies per mL) | |||
| <10,000 | 1,210 (23) | 474 (21) | 736 (24) |
| ≥10,000 | 4,163 (77) | 1,811(79) | 2,352 (76) |
| CD4 cell countb (mm3) at regimen initiation | |||
| ≥200 | 3804 (71) | 1507 (66) | 2297 (75) |
| <200 | 1551 (29) | 772 (34) | 779 (25) |
| Initiation Era (Year) | |||
| 2007–2009 | 1882 (35) | 1003 (44) | 879 (28) |
| 2010–2012 | 2135 (40) | 938 (41) | 1197 (39) |
| 2013–2015 | 1356 (25) | 344 (15) | 1012 (33) |
| Drug class | |||
| InSTI | 1110 (21) | 279 (12) | 831 (27) |
| InSTI/PI | 76 ( 1) | 49 ( 2) | 27 ( 1) |
| NNRTI | 2637 (49) | 1079 (47) | 1558 (50) |
| PI | 1547 (29) | 875 (39) | 672 (22) |
| Regimen | |||
| Dolutegravir/abacavir/lamivudine | 106 ( 2) | 11 ( 0) | 95 ( 3) |
| Atazanavir/ritonavir/emtricitabine/tenofovir | 665 (12) | 382 (17) | 283 ( 9) |
| Darunavir/ritonavir/emtricitabine/tenofovir | 546 (10) | 245 (11) | 301 (10) |
| Dolutegravir/emtricitabine/tenofovir | 89 ( 2) | 20 ( 1) | 69 ( 2) |
| Efavirenz/emtricitabine/tenofovir | 2173 (40) | 927 (41) | 1246 (40) |
| Elvitegravir/cobicistat/emtricitabine/tenofovir | 571 (11) | 69 ( 3) | 502 (16) |
| Raltegravir/emtricitabine/tenofovir | 286 ( 5) | 135 ( 6) | 151 ( 5) |
| Rilpivirine/emtricitabine/tenofovir | 336 ( 6) | 71 ( 3) | 265 ( 9) |
| Other | 601 (11) | 425 (19) | 176 ( 6) |
ART=anti-retroviral therapy; CNICS=CFAR Network of Integrated Systems; InSTI =integrase inhibitor; MSM=men having sex with men; PI=protease inhibitor; NNRTI= a non-nucleoside reverse transcriptase inhibitor; PLWH=people living with HIV/AIDS.
a
Patients in whom initial regimen was discontinued/modified or those who died while on the initial regimen were grouped as “Modified” while patients who remained on the initial regimen during the study period were grouped as “Continued.”
b
Missing data: Modified=6, Continued=12.